KVUE
Kenvue Inc.
NYSE · Consumer Defensive · Household & Personal Products · US
$18.74
−1.11%Sep 2, 2026, 01:15 UTC
The Australian Competition and Consumer Commission approved Kimberly-Clark Corporation's acquisition of Kenvue Inc., conditional on the divestiture of Kenvue's Carefree and Stayfree brands in Australia.
Aug 26, 2026, 19:50 UTC
Kimberly-Clark filed with the European antitrust regulator for review of its deal involving Kenvue.
Source:Aug 24, 2026, 17:00 UTC
BBB National Programs' National Advertising Division ruled on a challenge by Kenvue Inc., finding that Hims & Hers Health, Inc. had support for its comparative efficacy claim but recommending modification or discontinuance of other advertising claims.
Source:Aug 23, 2026, 03:50 UTC
India's food safety regulator FSSAI issued over 150 notices to major food and beverage companies including Nestle India, PepsiCo, Coca-Cola India, and Red Bull India for misleading advertisements, false claims, and labelling non-compliances.
Aug 20, 2026, 07:18 UTC
AssuredPartners Investment Advisors LLC acquired a new position of 32,710 shares in Kenvue Inc. (NYSE: KVUE), valued at approximately $625,000, as disclosed in a recent SEC filing.
Source:Aug 20, 2026, 03:15 UTC
Essity agreed to acquire Kenvue's feminine care business in Brazil, including the Carefree, Sempre Livre and o.b. brands, for USD 284 million on a cash and debt-free basis, expected to close in Q2 2027.
Aug 18, 2026, 07:50 UTC
B & T Capital Management DBA Alpha Capital Management acquired a new stake in Kenvue Inc. during the second quarter of 2026, purchasing 265,605 shares valued at approximately $5,076,000.
Source:Aug 12, 2026, 05:09 UTC
Meituan's core local commerce CEO Wang Puzhong announced at the Xipu Conference that Meituan is opening its AI business expert capabilities and CatPaw AI Agent platform to pharmaceutical merchants, with initial AI business experts already applied at Shuyu Pingmin and Kenvue.
Source:Aug 6, 2026, 10:45 UTC
Kenvue Inc. announced financial results for its fiscal second quarter ended June 28, 2026, reporting its third consecutive quarter of net and organic sales growth across all segments and regions.
Jul 29, 2026, 10:45 UTC
Kenvue Inc. announced a quarterly cash dividend of $0.21 per share, a 1.2% increase from the prior dividend, payable on August 26, 2026 to shareholders of record on August 12, 2026.
Source:Jul 24, 2026, 16:00 UTC
The U.S. Food and Drug Administration approved an over-the-counter fixed-dose combination pill of Kenvue's Tylenol and naproxen for pain relief.
Source:Jul 10, 2026, 20:30 UTC
The Illinois Appellate Court affirmed a $45 million jury verdict against Johnson & Johnson and Kenvue in a mesothelioma lawsuit brought by the family of Theresa Garcia.
Source: